SPOTLIGHT: Big4Bio:SFBay 2020 Year-in-Review

Welcome to the 2020 Big4Bio Year-in-Review for the San Francisco Bay Area! We hope you enjoy looking back on 2020’s top stories, deals, and M&A that went down in SFBay’s research, pharma, and biotech sectors as we head into 2021. Here’s what you’ll find inside the Year-in-Review 2020 report: Facts about the Bay Area’s life […]

Read More

SPOTLIGHT: Big4Bio:San Diego 2020 Year-in-Review

Welcome to the 2020 Big4Bio Year-in-Review for the San Diego region! We hope you enjoy looking back on 2020’s top stories, deals, and M&A that went down in San Diego’s research, pharma, and biotech sectors as we head into 2021. Here’s what you’ll find inside the Year-in-Review 2020 report: Facts about San Diego’s life sciences […]

Read More

SPOTLIGHT: Big4Bio:Boston 2020 Year-in-Review

Welcome to the 2020 Big4Bio Year-in-Review for the Boston area! We hope you enjoy looking back on 2020’s top stories, deals, and M&A that went down in Greater Boston’s research, pharma, and biotech sectors as we head into 2021. Here’s what you’ll find inside the Year-in-Review 2020 report: Facts about Greater Boston’s life sciences industry […]

Read More

SPOTLIGHT: Big4Bio:Philadelphia 2020 Year-in-Review

Welcome to the 2020 Big4Bio Year-in-Review for the Philadelphia area! We hope you enjoy looking back on 2020’s top stories, deals, and M&A that went down in Philadelphia’s research, pharma, and biotech sectors as we head into 2021. Here’s what you’ll find inside the Year-in-Review 2020 report: Facts about Greater Philadelphia’s life sciences industry The […]

Read More

Spotlight Q&A: TFF Pharmaceuticals – Innovative Drug Formulation May Expand Geographic Reach of COVID-19 Vaccines and Treatments

LaVoieHealthScience Client Spotlight Following is a Q&A with Glenn Mattes, President, CEO and Director of TFF Pharmaceuticals (Nasdaq: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform. Welcome to Big4Bio, Mr. Mattes. Can you share with our readers what is important about […]

Read More

Spotlight Q&A: John Hallinan, Chief Development Officer, Danforth Advisors

John Hallinan is the newly-named Chief Development Officer of Danforth Advisors, the life science industry’s leading resource for operational accounting, finance support and strategic CFO advisory. He was previously Chief Business Officer at Massachusetts Biotechnology Council (MassBio), representing the world’s premier life sciences hub, where he led efforts to catalyze early-stage innovation. He has more […]

Read More

Spotlight Q&A: John Hallinan, Chief Development Officer, Danforth Advisors

John Hallinan is the newly-named Chief Development Officer of Danforth Advisors, the life science industry’s leading resource for operational accounting, finance support and strategic CFO advisory. He was previously Chief Business Officer at Massachusetts Biotechnology Council (MassBio), representing the world’s premier life sciences hub, where he led efforts to catalyze early-stage innovation. He has more […]

Read More

Spotlight Q&A: Outlook Therapeutics — Developing First Ophthalmic Formulation of Bevacizumab for FDA Approval

LaVoieHealthScience Client Spotlight Following is a Q&A with Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics (NASDAQ: OTLK), a late-stage clinical biotech company focused on developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg to treat wet age-related macular degeneration (wet AMD) and other retinal diseases.  By way of background for our readers, age-related macular […]

Read More

Spotlight: Moving Towards a More Inclusive Life Sciences Industry

Get access to an ED&I toolkit from MassBio As our CEO, Tilton Little, was one of the 160+ life sciences CEOs that signed MassBio’s CEO Pledge for a More Equitable and Inclusive Life Sciences Industry, Big4Bio will work towards creating a more diverse life sciences industry. MassBio can help your company launch, analyze, and/or strengthen […]

Read More

Big4Bio-Area Companies Awarded NIH COVID-19 Test Contracts

From the NIH: “The National Institutes of Health is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus). NIH’s Rapid Acceleration of Diagnostics (RADx) initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests that could significantly increase […]

Read More

Big4Bio Q&A: Dror Bashan, CEO of Protalix BioTherapeutics

LaVoieHealthScience Client Spotlight with Dror Bashan, CEO of Protalix BioTherapeutics Can you provide a brief overview of Protalix BioTherapeutics and its focus? Protalix BioTherapeutics is a unique biopharmaceutical company dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with our ProCellEx® plant cell-based expression. Protalix was the first company ever to gain FDA approval for […]

Read More

Spotlight: 3.0 University Place

“In many ways, this project (3.0 University Place) is the most responsive to the needs of Philly’s burgeoning biotech and advanced life sciences sector” – 2020 PIDC/Commerce Department Life Science Report   About 3.0 University Place: 3.0 University Place — a 250,000+ sq ft, life sciences-enabled building (commercial lab and office trophy building) with LEED […]

Read More

Spotlight: Sikich — A Formula for Life Science Success

Sikich LLP is a 1000 member business advisory firm that offers technology and accounting services to a broad array of companies. In operation for more than 35 years, about 10 years ago the company started offering its services to life sciences companies, tailored to fit their specific needs. Big4Bio editor Marie Daghlian recently met virtually […]

Read More

Spotlight: Explora BioLabs — Powering Your Science

Explora BioLabs provides preclinical, AAALAC-accredited vivarium space and related services to clients of all sizes and in all stages of development. With 150,000 square feet of space across 11 locations in biotech-dense communities, the company prides itself on providing clients the ability to initiate preclinical in vivo programs in as little as two weeks, with […]

Read More